Article Text
PDF
Abstract
Many high-risk medical devices earn US marketing approval based on limited premarket clinical evaluation that leaves important questions unanswered. Rigorous postmarket surveillance includes registries that actively collect and maintain information defined by individual patient exposures to particular devices. Several prominent registries for cardiovascular devices require enrolment as a condition of reimbursement for the implant procedure, without informed consent. In this article, we focus on whether these registries, separate from their legal requirements, have an ethical obligation to obtain informed consent from enrolees, what is lost in not doing so, and the ways in which seeking and obtaining consent might strengthen postmarket surveillance in the USA.
- ethics
- clinical ethics
Statistics from Altmetric.com
Footnotes
Contributors Both authors contributed equally to the conception, drafting and revision of this manuscript and approve its final form.
Funding DK is supported in part by the Greenwall Faculty Scholars Program in Bioethics. DK also reports serving as a consultant to the Circulatory Systems Advisory Panel of the Food and Drug Administration, and to Firefly Health.
Competing interests This work was supported by the Greenwall Foundation.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available/not applicable.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Read the full text or download the PDF:
Other content recommended for you
- A systematic review of ICD complications in randomised controlled trials versus registries: is our ‘ real - world ’ data an underestimation
- The FDA approval process for medical devices: an inherently flawed system or a valuable pathway for innovation
- Affordability and availability of off - patent drugs in the United States — the case for importing from abroad: observational study
- Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure
- Implantable cardioverter defibrillators: risks accompany the life - saving benefits
- Understanding Food and Drug Administration Regulatory Requirements for an Investigational Device Exemption for Sponsor - Investigators
- Assessment of US pathway for approving medical devices for rare conditions
- Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators
- Quality of evidence behind FDA approvals varies widely
- Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration ’s recommendation: a cross-sectional analysis in New York